SymBio Pharmaceuticals Limited (JASDAQ:4582) announced a private placement to issue 106,952 units of 50th stock acquisition rights at issue price of ¥273 per stock acquisition right for gross proceeds of ¥29,197,896 on September 25, 2020. The transaction will include participation from returning investor, Inflexion II Fund L.P. for 27,391 stock acquisition rights , Flagship Asset Management Investment Association No. 89 for 9,251 stock acquisition rights, Investment Limited Partnership InfleXion II for 70,310, The transaction is expected to close on October 12, 2020. The stock acquisition rights are convertible into 2,000,002,400 common shares of the company at an initial exercise price of ¥187 yen per share. The company will issue stock acquisition rights through third-party allotment. The transaction has been approved by the board of directors of the company.